← Back to Search

FAZA PET Scan for Cervical Cancer

N/A
Waitlist Available
Led By Michael Milosevic, MD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
TNM (7th edition) cT1-4, N0-1, M0-1
Age ≥18 years
Must not have
Prior complete or partial hysterectomy
Carcinoma of the cervical stump
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a PET scan can show how much oxygen is in cervical cancer. Low oxygen levels may affect how well treatment works.

Who is the study for?
This trial is for adults with cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma) who plan to undergo radiotherapy and possibly chemotherapy. They should not have had previous cancer treatment and must be able to lie down for PET scans. Pregnant women are excluded.
What is being tested?
The study tests a special x-ray test called a PET scan using 18F-Fluoroazomycin Arabinoside (18F-FAZA) to detect low oxygen levels in cervical cancer tissue, which may affect the tumor's growth and treatment response.
What are the potential side effects?
Since this trial involves diagnostic imaging rather than drug therapy, typical side effects associated with medications are not expected. However, there might be discomfort from lying still during the PET scan or reactions related to the contrast agent used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer is in stages 1 to 4, may have spread to nearby lymph nodes, and might or might not have spread to distant parts of the body.
Select...
I am 18 years old or older.
Select...
I can sign and understand the consent form for this study.
Select...
I have not had chemotherapy for cervical cancer before joining this study.
Select...
My cervical cancer is of a specific type (squamous, adenocarcinoma, or adenosquamous).

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had a complete or partial hysterectomy.
Select...
I have cancer in the remaining part of my cervix after surgery.
Select...
I cannot lie on my back for more than 30 minutes.
Select...
I am currently taking the medication Antabuse.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PET FAZA imagingExperimental Treatment1 Intervention
PET FAZA imaging of tumor hypoxia in patients with cervix cancer

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,527 Previous Clinical Trials
503,516 Total Patients Enrolled
Michael Milosevic, MDPrincipal InvestigatorPrincess Margaret Hospital, University Health Network
10 Previous Clinical Trials
1,118 Total Patients Enrolled

Media Library

18F-Fluoroazomycin Arabinoside (18F-FAZA) Clinical Trial Eligibility Overview. Trial Name: NCT01549730 — N/A
Cervical Cancer Research Study Groups: PET FAZA imaging
Cervical Cancer Clinical Trial 2023: 18F-Fluoroazomycin Arabinoside (18F-FAZA) Highlights & Side Effects. Trial Name: NCT01549730 — N/A
18F-Fluoroazomycin Arabinoside (18F-FAZA) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01549730 — N/A
~3 spots leftby May 2026